Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de phase III sur Dato-DXd avec ou sans durvalumab par rapport au choix de chimiothérapie de l'investigateur en association avec le pembrolizumab chez des patientes atteintes d'un cancer du sein triple négatif PD-L1 positif, localement récurrent, inopérable ou métastatique

24 septembre 2026 mis à jour par: AstraZeneca

Une étude de phase III, ouverte et randomisée, sur le datopotamab Deruxtecan (Dato-DXd) avec ou sans durvalumab par rapport à la chimiothérapie choisie par l'investigateur (paclitaxel, nab-paclitaxel ou gemcitabine + carboplatine) en association avec le pembrolizumab chez les patients atteints de PD-L1 positif Cancer du sein triple négatif inopérable ou métastatique récidivant localement (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

Aperçu de l'étude

Description détaillée

The primary objective of the study is to demonstrate superiority of Dato-DXd + durvalumab relative to ICC + pembrolizumab by assessment of PFS as assessed by BICR in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

The study will be stratified based on geographic location (US/Canada/Europe vs. Dato-DXd monotherapy enrolling countries vs. rest of world), disease-free interval (DFI) history (de novo vs. prior DFI 6 to 12 months vs. prior DFI > 12 months), and prior PD-1/PD-L1 treatment for early stage TNBC (yes vs. no).

This study aims to see if Dato-DXd with durvalumab allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy and pembrolizumab. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.

Type d'étude

Interventionnel

Inscription (Estimé)

625

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: AstraZeneca Breast Cancer Study Locator Service
  • Numéro de téléphone: +1-877-400-4656
  • E-mail: az-bcsl@careboxhealth.com

Lieux d'étude

      • Cape Town, Afrique du Sud, 7570
        • Recrutement
        • Research Site
      • Johannesburg, Afrique du Sud, 2013
        • Recrutement
        • Research Site
      • Johannesburg, Afrique du Sud, 2196
        • Recrutement
        • Research Site
      • Johannesburg, Afrique du Sud, 2193
        • Recrutement
        • Research Site
      • Paarl, Afrique du Sud, 7646
        • Recrutement
        • Research Site
      • Pretoria, Afrique du Sud, 0081
        • Recrutement
        • Research Site
      • Pretoria, Afrique du Sud, 0081
        • Complété
        • Research Site
      • Düsseldorf, Allemagne, 40479
        • Retiré
        • Research Site
      • Essen, Allemagne, 45136
        • Retiré
        • Research Site
      • Georgsmarienhütte, Allemagne, 49124
        • Retiré
        • Research Site
      • Hamburg, Allemagne, 20357
        • Retiré
        • Research Site
      • Hanover, Allemagne, 30625
        • Retiré
        • Research Site
      • Heidelberg, Allemagne, 69120
        • Retiré
        • Research Site
      • Heilbronn, Allemagne, 74078
        • Retiré
        • Research Site
      • Leipzig, Allemagne, 04103
        • Retiré
        • Research Site
      • CABA, Argentine, 1425
        • Recrutement
        • Research Site
      • CABA, Argentine, 1414
        • Recrutement
        • Research Site
      • CABA, Argentine, C1425
        • Retiré
        • Research Site
      • CABA, Argentine, C1113AAE
        • Recrutement
        • Research Site
      • Ciudad Autónoma Buenos Aires, Argentine, C1430EFA
        • Recrutement
        • Research Site
      • Ciudad de Buenos Aires, Argentine, C1015ABO
        • Recrutement
        • Research Site
      • Rosario, Argentine, 2000
        • Recrutement
        • Research Site
      • San Nicolás de los Arroyos, Argentine, B2900
        • Retiré
        • Research Site
      • Camperdown, Australie, 2050
        • Recrutement
        • Research Site
      • Darlinghurst, Australie, 2010
        • Complété
        • Research Site
      • Heidelberg, Australie, 3084
        • Complété
        • Research Site
      • Melbourne, Australie, 3000
        • Recrutement
        • Research Site
      • Nedlands, Australie, 6009
        • Recrutement
        • Research Site
      • Waratah, Australie, 2298
        • Retiré
        • Research Site
      • Barretos, Brésil, 14784-400
        • Recrutement
        • Research Site
      • Curitiba, Brésil, 80730-150
        • Recrutement
        • Research Site
      • Florianópolis, Brésil, 88034-000
        • Recrutement
        • Research Site
      • Goiânia, Brésil, 74000-000
        • Recrutement
        • Research Site
      • Itajaí, Brésil, 88301-220
        • Recrutement
        • Research Site
      • Porto Alegre, Brésil, 90035-003
        • Recrutement
        • Research Site
      • Recife, Brésil, 52010-075
        • Recrutement
        • Research Site
      • São Paulo, Brésil, 01246-000
        • Recrutement
        • Research Site
      • São Paulo, Brésil, 01317-001
        • Recrutement
        • Research Site
      • Teresina, Brésil, 64049-200
        • Recrutement
        • Research Site
    • Ontario
      • Barrie, Ontario, Canada, L4M 6M2
        • Recrutement
        • Research Site
      • Hamilton, Ontario, Canada, L8V 5C2
        • Recrutement
        • Research Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Recrutement
        • Research Site
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Recrutement
        • Research Site
      • Montreal, Quebec, Canada, H4A 3J1
        • Recrutement
        • Research Site
      • Montreal, Quebec, Canada, H2X 0A9
        • Recrutement
        • Research Site
      • Québec, Quebec, Canada, G1S 4L8
        • Recrutement
        • Research Site
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4T 7T1
        • Recrutement
        • Research Site
      • Saskatoon, Saskatchewan, Canada, S7N 4H4
        • Recrutement
        • Research Site
      • Anyang, Chine, 455000
        • Recrutement
        • Research Site
      • Beijing, Chine, 100044
        • Recrutement
        • Research Site
      • Beijing, Chine, 100142
        • Recrutement
        • Research Site
      • Bengbu, Chine, 233004
        • Recrutement
        • Research Site
      • Changchun, Chine, 130021
        • Recrutement
        • Research Site
      • Changsha, Chine, 410008
        • Recrutement
        • Research Site
      • Changsha, Chine, 410013
        • Recrutement
        • Research Site
      • Chengdu, Chine, 610000
        • Recrutement
        • Research Site
      • Chengdu, Chine, 610041
        • Recrutement
        • Research Site
      • Chongqing, Chine, 400030
        • Retiré
        • Research Site
      • Fuzhou, Chine, 350014
        • Recrutement
        • Research Site
      • Guangzhou, Chine, 510120
        • Recrutement
        • Research Site
      • Guangzhou, Chine, 510060
        • Recrutement
        • Research Site
      • Guangzhou, Chine, 510700
        • Recrutement
        • Research Site
      • Hangzhou, Chine, 310009
        • Recrutement
        • Research Site
      • Hangzhou, Chine, 310022
        • Recrutement
        • Research Site
      • Hangzhou, Chine, 310016
        • Recrutement
        • Research Site
      • Harbin, Chine, 150081
        • Recrutement
        • Research Site
      • Hefei, Chine, 230031
        • Recrutement
        • Research Site
      • Jinan, Chine, 250021
        • Actif, ne recrute pas
        • Research Site
      • Meizhou, Chine, 514031
        • Recrutement
        • Research Site
      • Nanchang, Chine, 330009
        • Recrutement
        • Research Site
      • Nanjing, Chine, 210009
        • Recrutement
        • Research Site
      • Nanjing, Chine, 2100008
        • Recrutement
        • Research Site
      • Nanning, Chine, 530021
        • Recrutement
        • Research Site
      • Shandong, Chine
        • Recrutement
        • Research Site
      • Shanghai, Chine, 200025
        • Recrutement
        • Research Site
      • Shanghai, Chine, 200080
        • Complété
        • Research Site
      • Shenyang, Chine, 110004
        • Recrutement
        • Research Site
      • Taiyuan, Chine, 030000
        • Recrutement
        • Research Site
      • Tianjin, Chine, 300000
        • Recrutement
        • Research Site
      • Wenzhou, Chine, 325000
        • Recrutement
        • Research Site
      • Wuhan, Chine, 430022
        • Recrutement
        • Research Site
      • Wuhan, Chine, 430079
        • Recrutement
        • Research Site
      • Xi'an, Chine, 710061
        • Recrutement
        • Research Site
      • Xiamen, Chine, 361003
        • Recrutement
        • Research Site
      • Xintai, Chine, 54031
        • Recrutement
        • Research Site
      • Xuzhou, Chine, 221009
        • Recrutement
        • Research Site
      • Zhanjiang, Chine, 524003
        • Recrutement
        • Research Site
      • Zhengzhou, Chine, 450008
        • Recrutement
        • Research Site
      • Zhengzhou, Chine, 450052
        • Recrutement
        • Research Site
      • Busan, Corée du Sud, 49241
        • Complété
        • Research Site
      • Daegu, Corée du Sud, 41404
        • Recrutement
        • Research Site
      • Goyang-si, Corée du Sud, 10408
        • Recrutement
        • Research Site
      • Seongnam-si, Corée du Sud, 13620
        • Recrutement
        • Research Site
      • Seoul, Corée du Sud, 03080
        • Recrutement
        • Research Site
      • Seoul, Corée du Sud, 06351
        • Recrutement
        • Research Site
      • Seoul, Corée du Sud, 05505
        • Recrutement
        • Research Site
      • Seoul, Corée du Sud, 03722
        • Recrutement
        • Research Site
      • Seoul, Corée du Sud, 06591
        • Recrutement
        • Research Site
      • Seoul, Corée du Sud, 02841
        • Recrutement
        • Research Site
      • Seoul, Corée du Sud, 06273
        • Recrutement
        • Research Site
      • Barcelona, Espagne, 8035
        • Recrutement
        • Research Site
      • Barcelona, Espagne, 08028
        • Retiré
        • Research Site
      • Granada, Espagne, 18016
        • Recrutement
        • Research Site
      • Hospitalet deLlobregat, Espagne, 08907
        • Recrutement
        • Research Site
      • Madrid, Espagne, 28007
        • Recrutement
        • Research Site
      • Madrid, Espagne, 28034
        • Retiré
        • Research Site
      • Pamplona, Espagne, 31008
        • Recrutement
        • Research Site
      • Santander, Espagne, 39008
        • Recrutement
        • Research Site
      • Lille, France, 59000
        • Recrutement
        • Research Site
      • Lyon, France, 69373
        • Recrutement
        • Research Site
      • Montpellier, France, 34298
        • Recrutement
        • Research Site
      • Paris, France, 75020
        • Recrutement
        • Research Site
      • Saint-Herblain, France, 44805
        • Recrutement
        • Research Site
      • Toulouse, France, 31059
        • Recrutement
        • Research Site
      • Vandœuvre-lès-Nancy, France, 54511
        • Recrutement
        • Research Site
      • Villejuif, France, 94800
        • Recrutement
        • Research Site
      • Hong Kong, Hong Kong, 999077
        • Recrutement
        • Research Site
      • Calicut, Inde, 673601
        • Retiré
        • Research Site
      • Chennai, Inde, 600031
        • Recrutement
        • Research Site
      • Jaipur, Inde, 302004
        • Retiré
        • Research Site
      • Kochi, Inde, 682027
        • Retiré
        • Research Site
      • Kolkata, Inde, 700160
        • Retiré
        • Research Site
      • Kottayam, Inde, 686008
        • Recrutement
        • Research Site
      • Marg Jaipur, Inde, 302004
        • Recrutement
        • Research Site
      • Mohali, Inde, 160055
        • Recrutement
        • Research Site
      • Mysuru, Inde, 570017
        • Recrutement
        • Research Site
      • Nagpur, Inde, 440001
        • Recrutement
        • Research Site
      • Nashik, Inde, 422009
        • Recrutement
        • Research Site
      • New Delhi, Inde, 11029
        • Recrutement
        • Research Site
      • New Delhi, Inde, 110075
        • Recrutement
        • Research Site
      • Puducherry, Inde, 605006
        • Recrutement
        • Research Site
      • Surat, Inde, 395002
        • Recrutement
        • Research Site
      • Thiruvananthapuram, Inde, 695011
        • Recrutement
        • Research Site
      • Vadodara, Inde, 391760
        • Recrutement
        • Research Site
      • Visakhapatnam, Inde, 530053
        • Retiré
        • Research Site
      • Bergamo, Italie, 24127
        • Recrutement
        • Research Site
      • Empoli, Italie, 50053
        • Recrutement
        • Research Site
      • Milan, Italie, 20132
        • Recrutement
        • Research Site
      • Milan, Italie, 20141
        • Recrutement
        • Research Site
      • Modena, Italie, 41124
        • Retiré
        • Research Site
      • Naples, Italie, 80131
        • Recrutement
        • Research Site
      • Padova, Italie, 35128
        • Recrutement
        • Research Site
      • Reggio Emilia, Italie, 42123
        • Recrutement
        • Research Site
      • Roma, Italie, 00168
        • Recrutement
        • Research Site
      • Rozzano, Italie, 20089
        • Recrutement
        • Research Site
      • Akashi-shi, Japon, 673-8558
        • Recrutement
        • Research Site
      • Bunkyō City, Japon, 113-8431
        • Recrutement
        • Research Site
      • Bunkyō City, Japon, 113-8677
        • Recrutement
        • Research Site
      • Chiba, Japon, 260-8717
        • Recrutement
        • Research Site
      • Chūōku, Japon, 104-0045
        • Recrutement
        • Research Site
      • Fukuoka, Japon, 811-1395
        • Recrutement
        • Research Site
      • Fukushima, Japon, 960-1295
        • Recrutement
        • Research Site
      • Gifu, Japon, 501-1194
        • Recrutement
        • Research Site
      • Hidaka-shi, Japon, 350-1298
        • Recrutement
        • Research Site
      • Hiroshima, Japon, 734-8551
        • Recrutement
        • Research Site
      • Hiroshima, Japon, 730-8518
        • Recrutement
        • Research Site
      • Isehara-shi, Japon, 259-1193
        • Recrutement
        • Research Site
      • Kamogawa-shi, Japon, 296-8602
        • Recrutement
        • Research Site
      • Kashiwa, Japon, 277-8577
        • Recrutement
        • Research Site
      • Kitaadachi-gun, Japon, 362-0806
        • Recrutement
        • Research Site
      • Kumamoto, Japon, 860-8556
        • Recrutement
        • Research Site
      • Kurume-shi, Japon, 830-0011
        • Recrutement
        • Research Site
      • Kōtoku, Japon, 135-8550
        • Recrutement
        • Research Site
      • Matsuyama, Japon, 791-0280
        • Recrutement
        • Research Site
      • Nagoya, Japon, 466-8560
        • Recrutement
        • Research Site
      • Nagoya, Japon, 467-8602
        • Recrutement
        • Research Site
      • Niigata, Japon, 951-8566
        • Recrutement
        • Research Site
      • Nishinomiya-shi, Japon, 663-8501
        • Recrutement
        • Research Site
      • Okayama, Japon, 700-8558
        • Recrutement
        • Research Site
      • Osaka, Japon, 541-8567
        • Recrutement
        • Research Site
      • Osakasayama-shi, Japon, 589-8511
        • Recrutement
        • Research Site
      • Ota-shi, Japon, 373-8550
        • Recrutement
        • Research Site
      • Sapporo, Japon, 003-0804
        • Recrutement
        • Research Site
      • Sendai, Japon, 980-8574
        • Recrutement
        • Research Site
      • Shinagawa-ku, Japon, 142-8666
        • Recrutement
        • Research Site
      • Shinjuku-ku, Japon, 162-8655
        • Recrutement
        • Research Site
      • Shinjuku-ku, Japon, 160-0023
        • Recrutement
        • Research Site
      • Tsu, Japon, 514-8507
        • Recrutement
        • Research Site
      • Tsukuba, Japon, 305-8577
        • Recrutement
        • Research Site
      • Yokohama, Japon, 241-8515
        • Recrutement
        • Research Site
      • CD Mexico, Mexique, 04980
        • Recrutement
        • Research Site
      • Guadalajara, Mexique, 44670
        • Retiré
        • Research Site
      • Guadalajara, Mexique, 44638
        • Recrutement
        • Research Site
      • Mexico City, Mexique, 0 3100
        • Recrutement
        • Research Site
      • Mexico City, Mexique, 06760
        • Recrutement
        • Research Site
      • México, Mexique, 04700
        • Recrutement
        • Research Site
      • Tuxtla Gutiérrez, Mexique, 29090
        • Recrutement
        • Research Site
      • Bacolod, Philippines, 6100
        • Recrutement
        • Research Site
      • Cebu City, Philippines, 6000
        • Recrutement
        • Research Site
      • City of Muntinlupa, Philippines, 1780
        • Recrutement
        • Research Site
      • Manila, Philippines, 1000
        • Recrutement
        • Research Site
      • Quezon City, Philippines, 1112
        • Recrutement
        • Research Site
      • San Juan City, Philippines, 1502
        • Recrutement
        • Research Site
      • Bialystok, Pologne, 15-027
        • Retiré
        • Research Site
      • Bydgoszcz, Pologne, 85-796
        • Retiré
        • Research Site
      • Gdansk, Pologne, 80-952
        • Recrutement
        • Research Site
      • Gdynia, Pologne, 81-519
        • Retiré
        • Research Site
      • Konin, Pologne, 62-500
        • Retiré
        • Research Site
      • Krakow, Pologne, 31-501
        • Recrutement
        • Research Site
      • Krakow, Pologne, 31-115
        • Retiré
        • Research Site
      • Legnica, Pologne, 59-220
        • Retiré
        • Research Site
      • Lodz, Pologne, 90-302
        • Recrutement
        • Research Site
      • Lublin, Pologne, 20-090
        • Retiré
        • Research Site
      • Przemyśl, Pologne, 37-700
        • Retiré
        • Research Site
      • Warsaw, Pologne, 02-781
        • Recrutement
        • Research Site
      • Wroclaw, Pologne, 53-413
        • Retiré
        • Research Site
      • Cardiff, Royaume-Uni, CF14 2TL
        • Recrutement
        • Research Site
      • Chelsea, Royaume-Uni, SW3 6JJ
        • Recrutement
        • Research Site
      • Leicester, Royaume-Uni, Le5 4PW
        • Recrutement
        • Research Site
      • Liverpool, Royaume-Uni, L7 8YA
        • Résilié
        • Research Site
      • London, Royaume-Uni, EC1A 7BE
        • Recrutement
        • Research Site
      • London, Royaume-Uni, SW17 0QT
        • Retiré
        • Research Site
      • Oxford, Royaume-Uni, OX3 7LE
        • Suspendu
        • Research Site
      • Surrey, Royaume-Uni, GU2 7XX
        • Suspendu
        • Research Site
      • Sutton, Royaume-Uni, SM2 5PT
        • Recrutement
        • Research Site
      • Taunton, Royaume-Uni, TA1 5DA
        • Recrutement
        • Research Site
      • Singapore, Singapour, 169610
        • Recrutement
        • Research Site
      • Singapore, Singapour, 308433
        • Recrutement
        • Research Site
      • Singapore, Singapour, 217562
        • Recrutement
        • Research Site
      • Singapore, Singapour, 119228
        • Retiré
        • Research Site
      • Hsinchu, Taïwan, 300
        • Recrutement
        • Research Site
      • Kaohsiung City, Taïwan, 80756
        • Recrutement
        • Research Site
      • Taichung, Taïwan, 40447
        • Recrutement
        • Research Site
      • Tainan, Taïwan, 704
        • Recrutement
        • Research Site
      • Taipei, Taïwan, 100
        • Recrutement
        • Research Site
      • Taipei, Taïwan, 112
        • Recrutement
        • Research Site
      • Taipei, Taïwan, 10449
        • Recrutement
        • Research Site
      • Taipei, Taïwan, 11259
        • Recrutement
        • Research Site
      • Taoyuan, Taïwan, 333
        • Recrutement
        • Research Site
      • Bangkok, Thaïlande, 10210
        • Recrutement
        • Research Site
      • Bangkok, Thaïlande, 10400
        • Recrutement
        • Research Site
      • Bangkok, Thaïlande, 10330
        • Recrutement
        • Research Site
      • Bangkok, Thaïlande, 10700
        • Recrutement
        • Research Site
      • Chiang Mai, Thaïlande, 50200
        • Recrutement
        • Research Site
      • Dusit, Thaïlande, 10300
        • Recrutement
        • Research Site
      • Khon Kaen, Thaïlande, 40002
        • Recrutement
        • Research Site
      • Songkhla, Thaïlande, 90110
        • Recrutement
        • Research Site
      • Ankara, Turquie (Türkiye), 6200
        • Recrutement
        • Research Site
      • Ankara, Turquie (Türkiye), 06520
        • Recrutement
        • Research Site
      • Besevler Ankara, Turquie (Türkiye)
        • Recrutement
        • Research Site
      • Istanbul, Turquie (Türkiye), 34010
        • Recrutement
        • Research Site
      • Izmir, Turquie (Türkiye), 35575
        • Retiré
        • Research Site
      • Küçükçekmece, Turquie (Türkiye), 34295
        • Recrutement
        • Research Site
      • Samsun, Turquie (Türkiye), 55200
        • Recrutement
        • Research Site
      • Da Nang, Viêt Nam, 550000
        • Recrutement
        • Research Site
      • Hanoi, Viêt Nam, 100000
        • Recrutement
        • Research Site
      • Ho Chi Minh City, Viêt Nam, 700000
        • Recrutement
        • Research Site
      • Huế, Viêt Nam, 530000
        • Recrutement
        • Research Site
      • Hồ Chí Minh, Viêt Nam, 700000
        • Recrutement
        • Research Site
      • Viet Tri, Viêt Nam, 35000
        • Recrutement
        • Research Site
      • Vinh, Viêt Nam, 460000
        • Recrutement
        • Research Site
    • Alabama
      • Daphne, Alabama, États-Unis, 36526
        • Recrutement
        • Research Site
    • Arkansas
      • Springdale, Arkansas, États-Unis, 72762
        • Recrutement
        • Research Site
    • California
      • Duarte, California, États-Unis, 91010
        • Retiré
        • Research Site
      • Fountain Valley, California, États-Unis, 92708
        • Pas encore de recrutement
        • Research Site
      • Glendale, California, États-Unis, 91204
        • Recrutement
        • Research Site
      • Sacramento, California, États-Unis, 95817
        • Recrutement
        • Research Site
      • Santa Rosa, California, États-Unis, 95403
        • Retiré
        • Research Site
    • Colorado
      • Aurora, Colorado, États-Unis, 80012
        • Recrutement
        • Research Site
      • Denver, Colorado, États-Unis, 80210
        • Pas encore de recrutement
        • Research Site
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06510
        • Recrutement
        • Research Site
    • Florida
      • Altamonte Springs, Florida, États-Unis, 32701
        • Pas encore de recrutement
        • Research Site
      • Jacksonville, Florida, États-Unis, 32256
        • Retiré
        • Research Site
      • Miami, Florida, États-Unis, 33176
        • Recrutement
        • Research Site
      • Palm Bay, Florida, États-Unis, 32909
        • Retiré
        • Research Site
      • Plantation, Florida, États-Unis, 33324
        • Recrutement
        • Research Site
    • Georgia
      • Atlanta, Georgia, États-Unis, 30318
        • Suspendu
        • Research Site
    • Hawaii
      • Honolulu, Hawaii, États-Unis, 96819
        • Retiré
        • Research Site
    • Illinois
      • Chicago, Illinois, États-Unis, 60637
        • Recrutement
        • Research Site
      • Decatur, Illinois, États-Unis, 62526
        • Retiré
        • Research Site
      • Elmhurst, Illinois, États-Unis, 60126
        • Retiré
        • Research Site
      • Naperville, Illinois, États-Unis, 60540
        • Retiré
        • Research Site
    • Indiana
      • New Albany, Indiana, États-Unis, 47150
        • Retiré
        • Research Site
    • Iowa
      • Des Moines, Iowa, États-Unis, 50309
        • Recrutement
        • Research Site
    • Kentucky
      • Lexington, Kentucky, États-Unis, 40503
        • Retiré
        • Research Site
      • Louisville, Kentucky, États-Unis, 40202
        • Retiré
        • Research Site
      • Louisville, Kentucky, États-Unis, 40207
        • Retiré
        • Research Site
    • Louisiana
      • Baton Rouge, Louisiana, États-Unis, 70809
        • Recrutement
        • Research Site
      • Baton Rouge, Louisiana, États-Unis, 70808
        • Retiré
        • Research Site
    • Maryland
      • Baltimore, Maryland, États-Unis, 21215
        • Retiré
        • Research Site
      • Columbia, Maryland, États-Unis, 21044
        • Recrutement
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02111
        • Retiré
        • Research Site
      • Worcester, Massachusetts, États-Unis, 01655
        • Retiré
        • Research Site
    • Michigan
      • Detroit, Michigan, États-Unis, 48201
        • Recrutement
        • Research Site
      • Grand Rapids, Michigan, États-Unis, 49503
        • Retiré
        • Research Site
    • Minnesota
      • Saint Paul, Minnesota, États-Unis, 55109
        • Recrutement
        • Research Site
    • Mississippi
      • Hattiesburg, Mississippi, États-Unis, 39401
        • Retiré
        • Research Site
    • Missouri
      • St Louis, Missouri, États-Unis, 63129
        • Recrutement
        • Research Site
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87109
        • Recrutement
        • Research Site
    • New York
      • Albany, New York, États-Unis, 12206
        • Retiré
        • Research Site
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Research Site
      • Stony Brook, New York, États-Unis, 11794-7263
        • Recrutement
        • Research Site
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45219
        • Recrutement
        • Research Site
      • Cincinnati, Ohio, États-Unis, 45245
        • Recrutement
        • Research Site
      • Cleveland, Ohio, États-Unis, 44195
        • Recrutement
        • Research Site
    • Pennsylvania
      • York, Pennsylvania, États-Unis, 17403
        • Retiré
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, États-Unis, 02903
        • Recrutement
        • Research Site
    • Tennessee
      • Chattanooga, Tennessee, États-Unis, 37404
        • Recrutement
        • Research Site
      • Nashville, Tennessee, États-Unis, 37203
        • Recrutement
        • Research Site
    • Texas
      • Dallas, Texas, États-Unis, 75246
        • Recrutement
        • Research Site
      • Dallas, Texas, États-Unis, 75230
        • Retiré
        • Research Site
      • Dallas, Texas, États-Unis, 75246
        • Retiré
        • Research Site
      • El Paso, Texas, États-Unis, 79902
        • Recrutement
        • Research Site
      • Flower Mound, Texas, États-Unis, 75028
        • Retiré
        • Research Site
      • Fort Worth, Texas, États-Unis, 76104
        • Retiré
        • Research Site
      • Houston, Texas, États-Unis, 77054
        • Retiré
        • Research Site
      • Houston, Texas, États-Unis, 77090
        • Retiré
        • Research Site
      • Houston, Texas, États-Unis, 77098
        • Retiré
        • Research Site
      • Kingwood, Texas, États-Unis, 77339
        • Retiré
        • Research Site
      • McKinney, Texas, États-Unis, 75071
        • Retiré
        • Research Site
      • Sugar Land, Texas, États-Unis, 77479
        • Recrutement
        • Research Site
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22903
        • Recrutement
        • Research Site
      • Fairfax, Virginia, États-Unis, 22031
        • Recrutement
        • Research Site
      • Midlothian, Virginia, États-Unis, 23114
        • Recrutement
        • Research Site
      • Norfolk, Virginia, États-Unis, 23502
        • Recrutement
        • Research Site
      • Roanoke, Virginia, États-Unis, 24014
        • Recrutement
        • Research Site
    • Washington
      • Tacoma, Washington, États-Unis, 98405
        • Recrutement
        • Research Site
    • Wisconsin
      • Madison, Wisconsin, États-Unis, 53792
        • Retiré
        • Research Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria

  • Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.

  • ECOG PS 0 or 1.

  • Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).

  • PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.

  • No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.

    - Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.

  • Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).

  • Measurable disease as per RECIST 1.1.

  • Adequate bone marrow reserve and organ function.

  • Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.

Key Exclusion Criteria

  • As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.

  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before Cycle 1 Day 1 and of low potential risk for recurrence.

  • Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

    - Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

  • Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.

  • Active or uncontrolled hepatitis B or C virus infection.

  • Known HIV infection that is not well controlled.

  • Uncontrolled or significant cardiac disease.

  • History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.

  • Clinically severe pulmonary function compromise.

  • Clinically significant corneal disease.

  • Active or prior documented autoimmune or inflammatory disorders.

  • Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.

  • Any concurrent anti-cancer treatment.

  • Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.

  • Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dato-DXd + durvalumab

Arm 1: Dato-DXd + durvalumab

Provided in 100mg vials. IV infusion. Experimental drug.

Autres noms:
  • Datopotamab deruxtécan (Dato-DXd, DS-1062a)

Provided in 500mg vials. IV infusion. Experimental drug.

Autres noms:
  • MEDI4736
Comparateur actif: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab

Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

Expérimental: Dato-DXd

Arm 3: Dato-DXd

Provided in 100mg vials. IV infusion. Experimental drug.

Autres noms:
  • Datopotamab deruxtécan (Dato-DXd, DS-1062a)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression Free Survival (PFS)
Délai: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The comparison will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1 progression.

However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits.

The measure of interest is the HR of PFS.

From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Survival (OS)
Délai: From randomisation until the date of death due to any cause (anticipated to be up to 64 months).

OS is defined as the time from randomisation until the date of death due to any cause.

From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
Objective Response Rate (ORR)
Délai: From randomisation up until progression (anticipated to be up to 33 months).

ORR is defined as the proportion of participants who have a CR or PR, as determined by the BICR/investigator assessment, per RECIST 1.1.

From randomisation up until progression (anticipated to be up to 33 months).
Duration of Response (DoR)
Délai: From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).

DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause.

From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
Progression-Free Survival (PFS) by Investigator assessment
Délai: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause.

From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
Clinical Benefit Rate (CBR) at 24 weeks
Délai: From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).

CBR at 24 weeks is defined as the percentage of participants who have a CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/per investigator assessment and derived from the raw tumour data for at least 23 weeks after randomisation.

From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Délai: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in breast symptoms and arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration.

Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Délai: Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in pain as measured by the EORTC IL199.

Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Délai: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Délai: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to First Subsequent Therapy (TFST)
Délai: From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).

TFST is defined as the time from randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause.

From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
Time to Second Subsequent Therapy (TSST)
Délai: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).

TSST is defined as the time from randomisation until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
Progression Free Survival 2 (PFS2)
Délai: From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).

PFS2 will be defined as the time from the randomisation to the earliest progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice based on radiological or clinical progression.

From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
Pharmacokinetics of Dato-DXd in combination with durvalumab
Délai: From first dose to end of treatment (anticipated to be up to 33 months).

Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload) in plasma.

From first dose to end of treatment (anticipated to be up to 33 months).
Immunogenicity of Dato-DXd in combination with durvalumab
Délai: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Presence of antidrug antibodies for Dato-DXd (confirmatory results: positive or negative, titres).

From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
Délai: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Safety and tolerability will be evaluated in the safety population in terms of AEs.

From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

23 novembre 2023

Achèvement primaire (Estimé)

28 juillet 2027

Achèvement de l'étude (Estimé)

30 septembre 2030

Dates d'inscription aux études

Première soumission

23 octobre 2023

Première soumission répondant aux critères de contrôle qualité

23 octobre 2023

Première publication (Réel)

27 octobre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Délai de partage IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critères d'accès au partage IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner